The End of Alzheimer’s Disease: Nudging Strategies to Encourage Mass Participation in Clinical Trials
Article Sidebar
Main Article Content
Abstract
Characterized by amyloid plaques, tau tangles, and neuronal loss, Alzheimer’s disease (AD) presents a significant public health challenge, with ever-growing prevalence due to an aging global population. By the time cognitive impairment is detected, the disease’s pathology is already extensive and difficult to halt. Despite advances in research and drug development, participation in AD drug trials remains crucial for discovering effective treatments and preventive measures. This article explores how behavioral economics can be employed to raise global awareness about Alzheimer’s, motivate individuals to undergo testing, and encourage involvement in experimental drug trials. By integrating nudging strategies with creative educational approaches, this study aims to increase support for AD research.
Downloads
Article Details
This work is licensed under a Creative Commons Attribution 4.0 International License.
References
ADI. (2024). Dementia statistics. Alzheimer’s Disease International. https://www.alzint.org/about/dementia-facts-figures/dementia-statistics/
Korolev, I. O. (2014). Alzheimer’s disease: A clinical and basic science review. Medical Student Research Journal, 4, 24-33. http://msrj.chm.msu.edu/wp-content/uploads/2014/12/Fall-2014-Alzheimers-Disease.pdf
Alzheimer’s Association. (2023). 2023 Alzheimer’s disease facts and figures. Alzheimer’s Association Report, 14 March.
https://alz-journals.onlinelibrary.wiley.com/doi/epdf/10.1002/alz.13016
National Institute on Aging. (2024, January 19). What happens to the brain in Alzheimer's disease? National Institute on Aging. https://www.nia.nih.gov/health/alzheimers-causes-and-risk-factors/what-happens-brain-alzheimers-disease
Solomon, A., Mangialasche, F., Richard, E., Andrieu, S., Bennett, D. A., Breteler, M., Fratiglioni, L., Hooshmand, B., Khacha-turian, A. S., Schneider, L. S., Skoog, I., & Kivipelto, M. (2014). Advances in the prevention of Alzheimer’s disease and dementia. Journal of Internal Medicine, 275(3), 229-250. https://doi.org/10.1111/joim.12178
Mendez, M. F. (2019). Early-onset Alzheimer’s disease and its variants. Continuum (Minneap Minn), 25(1), 34-51. https://doi.org/10.1212/CON.0000000000000687
Raj, N. (2024, April). Effects of behavioral economics on decision-making. In Transforming Business Practices in Changing Global Economy. Two-day International Conference organized by the School of Management and Commerce, ITM University Gwalior.
Linnemayr, S., & Rice, T. (2016). Insights from behavioral economics to design more effective incentives for improving chronic health behaviors, with an application to adherence to antiretrovirals. Journal of Acquired Immune Deficiency Syndromes, 72(2), e50-e52. https://doi.org/10.1097/QAI.0000000000000972
Asch, D. (2016). Less logic, more health: How behavioral economics can improve incentives. Knowledge at Wharton. http://knowledge.wharton.upenn.edu/article/how-behavioral-economics-can-improve-health-incentives/
Ritchie, M. (2024). Utility of recruitment incentives in early Alzheimer’s disease. Alzheimer’s Association International Con-ference. https://alz.confex.com/alz/2024/meetingapp.cgi/Paper/92808
Thaler, R. H., & Sunstein, C. R. (2008). Nudge: Improving decisions about health, wealth, and happiness. Yale University Press.
Ménard, J.-F. (2010). A ‘nudge’ for public health ethics: Libertarian paternalism as a framework for ethical analysis of public health interventions? Public Health Ethics, 3(3), 229-238. https://doi.org/10.1093/phe/phq024
Rainford, P., & Tinkler, J. (2011). Designing for nudge effects: How behavior management can ease public sector problems. The London School of Economics and Political Science. http://eprints.lse.ac.uk/37810/1/Designing_for_nudge_effects_%28lsero%29.pdf
Keogh, B. (2017, October 11). Should you be ‘nudged’ into better health without you even knowing? The Conversation. https://theconversation.com/should-you-be-nudged-into-better-health-without-you-even-knowing-84601
Wachner, J., Adriaanse, M. A., & De Ridder, D. T. D. (2021). The effect of nudges on autonomy in hypothetical and real-life settings. PLoS ONE, 16(8), e0256124. https://doi.org/10.1371/journal.pone.0256124
Murayama, H., Takagi, Y., Tsuda, H., & Kato, Y. (2023). Applying nudge to public health policy: Practical examples and tips for designing nudge interventions. International Journal of Environmental Research and Public Health, 20(5), 3962. https://doi.org/10.3390/ijerph20053962
John, P., Cotterill, S., Moseley, A., Richardson, L., Smith, G., Stoker, G., & Wales, C. (2011). Nudge, nudge, think, think: Using experiments to change civic behavior. Bloomsbury Academic. https://doi.org/10.5040/9781849662284
Migala, J. (2017, May 18). The Charlie Sheen effect on HIV testing was equivalent to 7 World AIDS Days. Vice. https://tonic.vice.com/en_us/article/wnwkab/the-charlie-sheen-effect-on-hiv-testing-was-equivalent-to-7-world-aids-days
Belluck, P., Kaplan, S., & Robbins, R. (2021, July 19). How an unproven Alzheimer’s drug got approved. The New York Times. https://www.nytimes.com/2021/07/19/health/alzheimers-drug-aduhelm-fda.html#:~:text=New%20Alzheimer's%20Disease%20Treatment%20Approved,that%20attacks%20the%20disease%20process
Robbins, R. (2024, January 31). Biogen abandons its controversial Alzheimer’s drug Aduhelm. The New York Times. https://www.nytimes.com/2024/01/31/business/biogen-alzheimers-aduhelm.html#:~:text=adviser%20called%20the%20approval%20of,protocol%2C%E2%80%9D%20including%20unusually%20close%20collaboration
Raji, C. A., Leng, Y., Ashford, J. W., & Khalsa, D. S. (2024). Handbook of prevention and Alzheimer’s disease. Advances in Alzheimer’s Disease, 10. https://www.j-alz.com/
Hermes, S., Cady, J., Armentrout, S., O’Connor, J., Holdaway, S. C., Cruchaga, C., Wingo, T., & Greytak, E. M.; Alzheimer’s Disease Neuroimaging Initiative. (2024). Epistatic features and machine learning improve Alzheimer’s disease risk prediction over polygenic risk scores. Journal of Alzheimer’s Disease, 99(4), 1425-1440. https://doi.org/10.3233/JAD-230236
Li, D., Xie, Q., Xie, J., Ni, M., Wang, J., Gao, Y., Wang, Y., & Tang, Q. (2024). Cerebrospinal fluid proteomics identifies potential biomarkers for early-onset Alzheimer’s disease. Journal of Alzheimer’s Disease, 100(1), 261-277. https://doi.org/10.3233/JAD-240022
Hayes, K. (2017, July 14). Colombian family offers rare Alzheimer’s research opportunity: Unique genetic mutation allows for preventive medicine trial. AARP. https://www.aarp.org/health/brain-health/info-2017/genetic-mutation-prevent-alzheimers-fd.html
Reardon, S. (2018, March 27). Pioneering Alzheimer’s study in Colombia zeroes in on enigmatic protein. Nature. https://www.nature.com/articles/d41586-018-03848-4
API. (2024). The Alzheimer’s Prevention Initiative (API) autosomal dominant Alzheimer’s disease (ADAD) Colombia trial. Alzheimer’s Prevention Initiative. https://alzheimerspreventioninitiative.com/api-studies/adad-colombia-trial/
Reiman, E. M., Pruzin, J. J., Rios-Romenets, S., Brown, C., Giraldo, M., Acosta-Baena, N., Tobon, C., Hu, N., Chen, Y., Ghisays, V., Enos, J., Goradia, D. D., Lee, W., Luo, J., Malek-Ahmadi, M., Protas, H., Thomas, R. G., Chen, K., Su, Y., Boker, C., Mastroeni, D., Alvarez, S., Quiroz, Y. T., Langbaum, J. B., Sink, K. M., Lopera, F., & Tariot, P. N.; API ADAD Colombia Trial Group. (2023, May). A public resource of baseline data from the Alzheimer's Prevention Initiative Autosomal-Dominant Alz-heimer’s Disease Trial. Alzheimer’s & Dementia, 19(5), 1938-1946. https://doi.org/10.1002/alz.12843
Stam, C. J., & de Haan, W. (2024). Network hyperexcitability in early-stage Alzheimer's disease: Evaluation of functional con-nectivity biomarkers in a computational disease model. Journal of Alzheimer’s Disease, 99(4), 1333-1348. https://doi.org/10.3233/JAD-230825
Reiman, E. M., Cummings, J. L., Langbaum, J. B., Mattke, S., & Alexander, R. C. (2024, February). A chance to prevent Alz-heimer’s disease sooner than you think. Lancet Neurology, 23(2), 144-145. https://doi.org/10.1016/S1474-4422(23)00508-2
Parra, M. A., Butler, S., McGeown, W. J., Brown Nicholls, L. A., & Robertson, D. J. (2019, December). Globalizing strategies to meet global challenges: The case of ageing and dementia. Journal of Global Health, 9(2), 020310. https://doi.org/10.7189/jogh.09.020310
Sexton, C., Snyder, H., Chandrasekaran, L., Worley, S., & Carrillo, M. (2021). Expanding representation of low and middle in-come countries in global dementia research: Commentary from the Alzheimer’s Association. Frontiers in Neurology, 12, 633777. https://doi.org/10.3389/fneur.2021.633777
Llibre-Guerra, J. J., Heavener, A., Brucki, S. M. D., Marante, J. P. D., Pintado-Caipa, M., Chen, Y., Behrens, M. I., Hardi, A., Admirall-Sanchez, A., Akinyemi, R., Alladi, S., Dorsman, K. A., Rodriguez-Salgado, A. M., Solorzano, J., & Babulal, G. M.; Diversity and Disparity Professional Interest Area Increasing Sustained Diversity in Clinical Trials Working Group. (2023, July). A call for clinical trial globalization in Alzheimer's disease and related dementia. Alzheimer’s & Dementia, 19(7), 3210-3221. https://doi.org/10.1002/alz.12995
Cummings, J. (2019). The role of biomarkers in Alzheimer’s disease drug development. Advances in Experimental Medicine and Biology, 1118, 29-61. https://doi.org/10.1007/978-3-030-05542-4_2
ASPE. (2024, April 22). National plan to address Alzheimer’s disease: 2023 update. Office of the Assistant Secretary for Planning and Evaluation. https://aspe.hhs.gov/reports/national-plan-2023-update
Rossiter, J. R. (2019). A critique of prospect theory and framing with particular reference to consumer decisions. Journal of Consumer Behavior: An International Research Review, 18(5), 399-405. https://doi.org/10.1002/cb.1817
Selten, R. (1990). Bounded rationality. Journal of Institutional and Theoretical Economics (JITE) / Zeitschrift für die gesamte Staatswissenschaft, 146(4), 649–658. http://www.jstor.org/stable/40751353
Kahneman, D., Knetsch, J. L., & Thaler, R. H. (1991). Anomalies: The endowment effect, loss aversion, and status quo bias. Journal of Economic Perspectives, 5(1), 193-206.
Kahneman, D. (2013). Thinking, fast and slow. Farrar, Straus and Giroux.
Golman, R., Hagmann, D., & Loewenstein, G. (2017). Information avoidance. Journal of Economic Literature, 55(1), 96-135. https://doi.org/10.1257/jel.20151245
HE. (2024). Heuristic Encyclopedia: Find everything you wanted to know about a heuristic. Newristics. https://newristics.com/heuristics-biases/empathy-gap
Norton, M. I., Mochon, D., & Ariely, D. (2012). The IKEA effect: When labor leads to love. Journal of Consumer Psychology, 22(3), 453-460.
Bedekar, M., & Joshi, P. (2020). Cartoon films and their impact on children’s mentality. International Journal of Multidiscipli-nary, 5(6), 13-18. https://doi.org/10.31305/rrijm.2020.v05.i06.003
Chakravorty, D., & Tilak, G. (2021). Socio-cultural effects of visual representation through animated films with special reference to movies Inside Out & Zootopia. International Journal of Future Generation Communication and Networking, 14(1), 2636-2642.
Mishra, P., Singh, U., Pandey, C. M., Mishra, P., & Pandey, G. (2019). Application of student’s t-test, analysis of variance, and covariance. Annals of Cardiac Anaesthesia, 22(4), 407-411. https://doi.org/10.4103/aca.ACA_94_19
Manikandan, S. (2011). Measures of dispersion. Journal of Pharmacology & Pharmacotherapeutics, 2(4), 315-316. https://doi.org/10.4103/0976-500X.85931